Marshall Financial Group LLC Regeneron Pharmaceuticals, Inc. Transaction History

Marshall Financial Group LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	BUY	$902.69 - $993.35 $81,242 - $89,401	90 Added 9.66%	1,022 $983,000
Q4 2023 Jan 10, 2024	BUY	$775.18 - $881.7 $55,037 - $62,600	71 Added 8.25%	932 $818,000
Q3 2023 Oct 19, 2023	BUY	$692.45 - $844.37 $7,616 - $9,288	11 Added 1.29%	861 $708,000
Q2 2023 Jul 17, 2023	BUY	$700.03 - $830.35 $32,201 - $38,196	46 Added 5.72%	850 $610,000
Q1 2023 Apr 18, 2023	BUY	$680.49 - $826.97 $547,113 - $664,883	804 New	804 $660,000
Q2 2022 Jul 25, 2022	SELL	$548.35 - $738.84 $967,289 - $1.3 Million	-1,764 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$595.12 - $698.43 $42,253 - $49,588	71 Added 4.19%	1,764 $1.23 Million
Q4 2021 Jan 27, 2022	BUY	$543.48 - $670.97 $129,891 - $160,361	239 Added 16.44%	1,693 $1.07 Million
Q3 2021 Oct 28, 2021	BUY	$574.03 - $680.96 $65,439 - $77,629	114 Added 8.51%	1,454 $880,000
Q2 2021 Jul 14, 2021	BUY	$472.8 - $558.54 $633,552 - $748,443	1,340 New	1,340 $748,000

1,529

82.7M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $74.7B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Marshall Financial Group LLC, based on Form 13F filings with the SEC.

Stay updated on Marshall Financial Group LLC with notifications on news.